Related Experiment Videos
Ticarcillin-clavulanic acid therapy in severe infections
Drugs Under Experimental and Clinical Research
|January 1, 1985
Summary
Ticarcillin plus clavulanic acid effectively treated severe infections in most patients, including those with underlying diseases and bacteremia. Some patients infected with resistant bacteria did not respond, and mild side effects were noted.
Area of Science:
- Infectious Diseases
- Pharmacology
- Internal Medicine
Background:
- Severe infections pose significant treatment challenges, especially in patients with comorbidities.
- Antimicrobial resistance, including resistance to ticarcillin, complicates treatment decisions.
- The combination of ticarcillin and clavulanic acid offers a broader spectrum of activity.
Purpose of the Study:
- To evaluate the efficacy and safety of a fixed combination of ticarcillin and clavulanic acid in patients with severe infections.
- To assess treatment outcomes in a patient cohort with significant underlying diseases and bacteremia.
Main Methods:
- A prospective study involving twenty patients with severe infections.
- Treatment administered: fixed combination of ticarcillin + clavulanic acid.
- Outcomes assessed: clinical cure, improvement, failure, and adverse events.
Main Results:
- Fifteen patients had bacteremia, with four in shock.
- Eleven patients were infected with microorganisms resistant in vitro to ticarcillin.
- Clinical cure was achieved in eleven patients; six improved, and three failed to respond (all infected with resistant strains).
Conclusions:
- Ticarcillin plus clavulanic acid demonstrated clinical utility in severe infections, even in complex patient populations.
- Treatment failure was associated with ticarcillin-resistant microorganisms.
- The combination was generally well-tolerated, with mostly mild and reversible side effects.